The Mechanism of a Novel Mitochondrial-Targeted Icaritin Derivative in Regulating Apoptosis of BEL-7402 Cells Based on the SIRT3 and CypD-Mediated ROS/p38 MAPK Signaling Pathway

Zenan Chen, Wei Li, Yan Zhao, Dingrui Liu, Jiahong Han, Enbo CaiMolecules 2025 · DOI

TL;DR

Researchers have developed a novel mitochondrial-targeted derivative of icaritin (Mito-ICT-4) that shows significantly enhanced anti-cancer activity against liver cancer cells (BEL-7402) with improved selectivity over normal cells. This derivative works by disrupting mitochondrial function, increasing reactive oxygen species (ROS), and activating the p38 MAPK signaling pathway, ultimately triggering cancer cell death.

What Problem Does This Paper Address?

Liver cancer remains a major global health challenge with a low survival rate, largely due to the lack of effective targeted therapies and the significant toxic side effects of current treatments. Mitochondria, crucial for cancer cell survival and proliferation, are considered prime targets for cancer therapy. However, existing drugs often lack sufficient selectivity for tumor cells, leading to damage to healthy tissues and limiting their therapeutic potential. This paper addresses the need for more targeted and effective anti-cancer agents by developing a modified icaritin molecule designed to specifically accumulate in tumor cell mitochondria.

Methods

The study employed a multi-pronged approach:

  • Chemical Synthesis: Twelve novel icaritin (ICT) derivatives were designed and synthesized, with four specifically modified to target mitochondria using a triphenylphosphine (TPP+) moiety. Fatty acid analogs were also synthesized for comparison.
  • In Vitro Biological Activity: The antiproliferative effects of these compounds were evaluated against four human cancer cell lines (A549, PC-3M, MCF-7, and BEL-7402) and one normal cell line (HEK293) using the MTT assay.
  • Mitochondrial Targeting and Distribution: High-performance liquid chromatography (HPLC) was used to quantify the accumulation of Mito-ICT-4 within the mitochondria of BEL-7402 cells compared to the parent ICT.
  • Mitochondrial Function Assays: The impact of Mito-ICT-4 on mitochondrial membrane potential was assessed using JC-1 staining, and mitochondrial permeability transition pore (MPTP) opening was evaluated using Calcein AM and CoCl2.
  • Apoptosis Assays: Apoptosis induction was measured using DAPI staining and Annexin V-FITC/PI double staining followed by flow cytometry. Western blot analysis was used to assess the expression of key apoptosis-related proteins like cleaved caspase-3.
  • ROS Measurement: Intracellular reactive oxygen species (ROS) levels were quantified using flow cytometry with ROSup as a positive control.
  • Molecular Docking: Computational molecular docking was performed to predict the binding interactions of Mito-ICT-4 with key proteins involved in mitochondrial function and signaling pathways (SIRT3, CypD, MKK6, P38, DDIT3).
  • Transcriptome Sequencing: RNA sequencing was conducted on BEL-7402 cells treated with Mito-ICT-4 to identify differentially expressed genes and enriched pathways.
  • Gene Expression Validation: Quantitative real-time PCR (qRT-PCR) and Western blot analysis were used to validate the expression levels of key genes identified through transcriptome sequencing (SIRT3, CypD, MKK6, P38, DDIT3).

Datasets

The study utilized established human cancer cell lines (A549, PC-3M, MCF-7, BEL-7402) and a normal renal cell line (HEK293). These cell lines were obtained from commercial collections. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Mitochondrial Targeting is Key: The introduction of the triphenylphosphine (TPP+) moiety significantly enhances the antitumor activity and selectivity of icaritin derivatives, demonstrating the power of targeted drug delivery to mitochondria.
  • Chain Length Matters: The length of the alkyl chain linking icaritin and TPP+ plays a role in determining antitumor potency, with longer chains generally conferring stronger activity.
  • Mito-ICT-4: A Potent and Selective Agent: Mito-ICT-4 emerged as the most promising derivative, exhibiting remarkable potency against liver cancer cells (BEL-7402) and a substantial selectivity advantage over normal cells.
  • Mechanism Unveiled: The study elucidated a detailed mechanism of action: Mito-ICT-4 enters mitochondria, downregulates SIRT3, increases ROS, triggers CypD-dependent MPTP opening, depolarizes mitochondrial membrane potential, and ultimately activates the p38 MAPK pathway to induce apoptosis.
  • SIRT3-ROS Axis as a Novel Target: The research highlights a novel mechanism involving the regulation of the SIRT3-ROS axis by icaritin derivatives for anti-cancer effects.

Key Results

  • Enhanced Potency and Selectivity: Mito-ICT-4 showed an IC50 of 0.73 ± 0.06 µM in BEL-7402 cells, which is 29 times lower than that of the parent ICT. It also demonstrated approximately 33-fold selectivity for tumor cells over normal HEK293 cells (IC50 of 67.11 ± 2.09 µM).
  • Mitochondrial Accumulation: Mito-ICT-4 accumulated in BEL-7402 cell mitochondria approximately 2.5 times more than ICT.
  • Apoptosis Induction: Mito-ICT-4 significantly promoted apoptosis in BEL-7402 cells, with a total apoptosis rate of 27.39% observed at the high-dose group. Cleaved caspase-3 expression was significantly upregulated.
  • ROS Upregulation: Intracellular ROS levels were significantly elevated in a dose-dependent manner in BEL-7402 cells treated with Mito-ICT-4.
  • SIRT3 Downregulation: Mito-ICT-4 treatment led to a significant decrease in SIRT3 protein expression.
  • CypD Upregulation and MPTP Opening: CypD protein expression was elevated, leading to abnormal MPTP opening and increased mitochondrial membrane permeability.
  • MAPK Pathway Activation: Transcriptome sequencing and subsequent validation revealed that Mito-ICT-4 influences the MAPK signaling pathway, specifically downregulating SIRT3, p-MKK6, and p-p38, while upregulating CypD and DDIT3.

Limitations and Future Work

  • In Vivo Studies: While promising in vitro results were obtained, the paper does not present in vivo studies to confirm the efficacy and safety of Mito-ICT-4 in animal models.
  • Broader Cell Line Screening: Although four cancer cell lines were tested, further investigation across a wider range of cancer types could provide a more comprehensive understanding of Mito-ICT-4's potential.
  • Optimization of Synthesis: While the synthesis of intermediates and fatty acid ester derivatives showed some selectivity issues with varying alkyl chain lengths, the optimized conditions for Mito-ICT-4 synthesis yielded higher results. Further optimization of the synthesis of all derivatives could be explored.
  • Long-Term Effects: The study focused on 48-hour treatment. Investigating the long-term effects and potential for resistance development would be valuable.

The authors suggest that these novel mitochondria-targeting ICT derivatives, particularly Mito-ICT-4, provide a strong foundation for the development of targeted antitumor drugs. Future work could focus on translating these findings into preclinical and clinical applications.

Summary updated

Abstract

Tumorigenesis and progression are closely associated with apoptosis and primarily regulated by mitochondria, which are considered major targets for cancer therapy. In this study, twelve novel icaritin (ICT) derivatives were designed and synthesized, four of which were specifically targeted to mitochondria. Biological studies demonstrated that all compounds containing triphenylphosphine (TPP<sup>+</sup>) exhibited a substantial increase in antitumor activity compared to ICT and control compounds while also exhibiting notable selectivity for tumor cells over normal cells. Among these derivatives, Mito-ICT-4 exhibited the strongest antiproliferative effect, with an IC<sub>50</sub> value of 0.73 ± 0.06 μM for BEL-7402 cells, which is 29 times lower than that of ICT, and an IC<sub>50</sub> value of 67.11 ± 2.09 μM for HEK293 cells, indicating approximately 33-fold selectivity for tumor cells. High-performance liquid chromatography (HPLC) analysis revealed that Mito-ICT-4 significantly accumulated in the mitochondria of BEL-7402 cells, with the level of accumulation approximately 2.5 times greater than that of ICT. Further investigations demonstrated that upon entering the mitochondria of tumor cells, Mito-ICT-4 downregulated SIRT3 protein expression, disrupted intracellular redox homeostasis, and led to a substantial increase in mitochondrial ROS levels, abnormal CypD-dependent MPTP opening, mitochondrial membrane potential depolarization, and ROS release into the cytoplasm, ultimately triggering ROS-mediated apoptosis in BEL-7402 cells. Transcriptomic analysis identified differentially expressed genes and enriched pathways, highlighting the ROS-mediated p38-MAPK signaling pathway as a key mediator of Mito-ICT-4-induced mitochondria-dependent apoptosis. The effects of Mito-ICT-4 on the expression of key genes (SIRT3, CypD, P-MKK6, P-P38, and DDIT3) were further validated by qRT-PCR and Western blot analysis, with results aligning with transcriptomic data. The novel ICT derivatives synthesized in this study, with mitochondria-targeting functionality, provide a basis for the development of targeted antitumor drugs.
BibTeX
@inproceedings{chen2025mechanism,
  author = {Zenan Chen and Wei Li and Yan Zhao and Dingrui Liu and Jiahong Han and Enbo Cai},
  title = {{The Mechanism of a Novel Mitochondrial-Targeted Icaritin Derivative in Regulating Apoptosis of BEL-7402 Cells Based on the SIRT3 and CypD-Mediated ROS/p38 MAPK Signaling Pathway}},
  booktitle = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30081667},
}
Figure